996MO Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced/metastatic solid tumors: Data from phase I dose escalation
Year: 2024
Type: article
Source: Annals of Oncology
Authors: J.J. Luke, X. Gao, A.J. Olszanski, R.E. Sanborn, G.S. Falchook, S. Patel, P.L. Bedard, D. Orr, J.P. Gibbs, C. Li, Y-C. Huang, R. Gregory, R. Ramesh, R. Xu, B. Wu, K. Ding, J. Raizer, P. Lorusso
Institutions: University of Pittsburgh, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Massachusetts General Hospital, Fox Chase Cancer Center, HealthONE, Moores Cancer Center, University Health Network, Mary Crowley Cancer Research Center, Takeda (United States), Yale Cancer Center, Yale University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4402561069